Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer
Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.
You may also be interested in...
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The diagnostics company said the test is scheduled for US launch in Q4 2020.
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.